CLINICAL DATA
ARESTIN® helps kill the bacteria that SRP can leave behind4
ARESTIN® delivers minocycline directly to infected pockets, providing safe, localized drug concentrations at the site of the infection.1,4,21 ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg stays in place and maintains therapeutic drug concentrations for up to 21 days.5
ARESTIN® kills the pathogens most commonly associated with periodontal disease
Minocycline achieves minimum inhibitory concentration (MIC) levels well above those reported for common periodontal pathogens.20
Concentrations of minocycline in gingival crevicular fluid (GCF) at site of administration5
Red Complex Bacteria
ARESTIN® kills the red complex bacteria—P gingivalis, T denticola, and T forsynthensis—clinically associated with important parameters of periodontal diagnosis, such as pocket depth and bleeding on probing.2,15
In a recent microbiological study of 127 patients with moderate-to-severe periodontitis and at least 5 teeth with =5 mm pocket depths, ARESTIN® + scaling and root planing (SRP) significantly reduced the quantity (P=0.002) and proportions (P=0.0005) of red complex bacteria vs SRP alone.2
In the same study, ARESTIN® also reduced pocket depths and bleeding on probing, and increased clinical attachment levels.3
Pocket Depth
The efficacy of ARESTIN® was measured in a controlled clinical study of 748 patients with moderate or advanced periodontitis and bleeding on probing. Scaling and root planing (SRP) was performed at baseline. Clinical assessments were conducted at baseline and 1, 3, 6, and 9 months. ARESTIN® was administered to all sites with pocket depths =5 mm.1
- ARESTIN® + SRP demonstrated significant pocket depth reductions vs SRP alone throughout 9 months (P<0.01)1
- Over 60% of pockets that responded to ARESTIN® + SRP had a reduction of =2 mm1
ARESTIN® is proven effective in deep pockets and in difficult-to-treat patient groups
- ARESTIN® + SRP is nearly 3 times more likely to reduce mean probing depths from =6 mm to <5 mm vs SRP alone1
- ARESTIN® + SRP provided a greater therapeutic effect than SRP alone in difficult-to-treat patient
groups1,22-24 - Based on pocket depth reduction scores at 9 months.†
Compared to SRP alone, the addition of ARESTIN® was more than 4 times more likely to reduce pockets to <5 mm in smokers.5‡
*Adapted from Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol 2001;72:1535-1544. Change in pocket depth from baseline to 9 months was recorded for ARESTIN® + SRP and SRP alone. Therapeutic effect was derived by calculating the percent difference between the 9-month scores.
† 748 patients with moderate or advanced periodontitis with bleeding on probing. SRP was performed at baseline. Clinical assessments were conducted at baseline and 1, 3, 6, and 9 months. ARESTIN® was administered to all sites with pocket depths =5 mm.
‡ Multivariate analysis of the univariate, multicenter Phase III trials of ARESTIN® + SRP to SRP + placebo and SRP alone. Odds ratios were adjusted for the simultaneous effect of influential variable such as treatment center, smoking status, age, and baseline pocket depths.